Evidence map›Paper›PMID 31956474›Full record

ArticleJournal of bone oncology2020

The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target.

Richert Iseulys, Gomez-Brouchet Anne, Bouvier Corinne, Du Bouexic De Pinieux Gonzague, Karanian Marie, Blay Jean-Yves, Dutour Aurélie

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Richert IseulysCRCL/CLB INSERM, Cell Death and Pediatric Cancers Team, U1052, UMR5286, CNRS U5286, 28 rue Laennec, 69373 Lyon cedex 8, France.
Gomez-Brouchet AnneDepartment of Pathology, IUCT-Oncopole, CHU of Toulouse, Université de Toulouse 3, UMR1037 INSERM, ERL5294 CNRS, Toulouse, France.
Bouvier CorinneDepartment of Pathology, APHM La Timone, Aix Marseille University, MMG, France.
Du Bouexic De Pinieux GonzagueDepartment of Pathology, Centre Hospitalier Universitaire Tours, 37000 Tours, France.
Karanian MarieDepartment of Pathology, Centre Léon Bérard, Lyon, France.
Blay Jean-YvesCRCL/CLB INSERM, Cell Death and Pediatric Cancers Team, U1052, UMR5286, CNRS U5286, 28 rue Laennec, 69373 Lyon cedex 8, France.
Dutour AurélieCRCL/CLB INSERM, Cell Death and Pediatric Cancers Team, U1052, UMR5286, CNRS U5286, 28 rue Laennec, 69373 Lyon cedex 8, France.
Centre Léon Bérard · FRAix-Marseille Université · FRCentre Hospitalier Universitaire de Tours · FRCentre National de la Recherche Scientifique · FRInserm · FRUniversité de Toulouse · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival rate for Chondrosarcoma (CHS) is at a standstill, more effective treatments are urgently needed. Consequently, a better understanding of CHS biology and its immune environment is crucial to identify new prognostic factors and therapeutic targets. Here, we exhaustively describe the immune landscape of conventional and dedifferentiated CHS. Using IHC and molecular analyses (RT-qPCR), we mapped the expression of immune cell markers (CD3, CD8, CD68, CD163) and immune checkpoints (ICPs) from a cohort of 27 conventional and 49 dedifferentiated CHS. The impact of the density of tumor-infiltrating lymphocytes (TILs), tumor-associated macrophages (TAMs) and immune checkpoints (ICPs) on clinical outcome were analyzed. We reveal that TAMs are the main immune population in CHS. Focusing on dedifferentiated CHS, we found that immune infiltrate composition is correlated with patient outcome, a high CD68+/CD8+ ratio being an independent poor prognostic factor (

Indexed as

APC, Antigen Presenting CellsB7H3, B7 superfamily member-H3CD, Cluster of DifferentiationCHS, ChondrosarcomaCSF1, Colony Stimulating Factor 1CSF1R, Colony Stimulating Factor 1 ReceptorCTLA4, cytotoxic T-lymphocyte–associatedHH, hedgehogHLA, Human Leucocytes AntigenICOS, Inducible CostimulatorICOSL, inducible costimulator ligandICP, Immune checkpointIDH, isocitrate deshydrogenaseLAG3, Lymphocyte activation gene-3MDR1, Multi Drug Resistance 1mTOR, mammalian Target Of RapamycinPD1, Programmed death 1PDL1, Programmed Death Ligand 1SIRPa, Signal regulatory protein alphaSMO, Smoothened Homolog PrecursorTAMs, Tumor Associated MacrophagesTILs, Tumor Infiltrating LymphocytesTIM3, T cell immunoglobulin mucinTreg, T regulator lymphocytes

Identifiers

PMID31956474
PMCPMC6961717
OpenAlexW2989902150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.